Physician profile
Jonathan A Rosenberg
NPI 1811150725
$1,019,412.00
in general payments reported to CMS, 2019-2025
66 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $152K · 2020: $60K · 2021: $91K · 2022: $121K · 2023: $213K · 2024: $243K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $469K · Travel and Lodging: $51K · Consulting Fee: $47K · Food and Beverage: $20K · Honoraria: $5,200 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,025 · Education: $95.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $468,982.50 |
| Travel and Lodging | $50,712.96 |
| Consulting Fee | $46,787.35 |
| Food and Beverage | $20,333.69 |
| Honoraria | $5,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,025.00 |
| Education | $95.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $156,673.61 | 2019-2025 | Skyrizi, Viberzi, Rinvoq |
| Nestle Healthcare Nutrition INC. | $156,492.35 | 2020-2023 | |
| Allergan, INC. | $136,261.54 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $111,527.31 | 2021-2024 | Zeposia, Camzyos |
| Aimmune Therapeutics, INC. | $105,664.64 | 2022-2025 | Zenpep |
| Lilly USA, LLC | $60,190.23 | 2023-2025 | Omvoh, Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $53,916.91 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $52,006.25 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49,642.71 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Genzyme Corporation | $33,573.69 | 2022-2025 | |
| Janssen Biotech, INC. | $30,666.21 | 2019-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $21,300.97 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $19,199.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $6,253.87 | 2019-2024 | Rebyota |
| Pfizer INC. | $5,093.06 | 2019-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $4,321.64 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $2,670.05 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Watchman Access System |
| Biocon Biologics INC | $2,593.35 | 2024 | Yesintek |
| Horizon Therapeutics Plc | $2,409.46 | 2019 | |
| Abbott Laboratories | $2,219.18 | 2020-2022 | |
| Ardelyx, INC. | $1,839.48 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $1,197.28 | 2021 | |
| Abiomed | $690.79 | 2019-2023 | Impella |
| Ge Healthcare | $337.00 | 2023 | |
| Qol Medical, LLC | $315.61 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $305.04 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $268.30 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $211.60 | 2021 | |
| Shockwave Medical, INC | $163.28 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $159.54 | 2021-2025 | Vitalflow Console, Gi Genius, Bravo |
| Braintree Laboratories, INC. | $141.18 | 2019-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $110.05 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $97.31 | 2020-2025 | Onpattro |
| Vivus LLC | $95.11 | 2022-2025 | Qsymia |
| Ucb, INC. | $85.44 | 2019 | |
| Shionogi INC | $83.82 | 2019-2020 | |
| Celltrion USA INC. | $79.25 | 2023-2025 | Vegzelma, Yuflyma |
| Daiichi Sankyo INC. | $77.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $67.91 | 2019-2024 | |
| Heartflow, INC. | $61.05 | 2022 | |
| Angiodynamics, INC. | $47.53 | 2025 | Alphavac |
| Dova Pharmaceuticals | $39.61 | 2019 | |
| Teleflex LLC | $37.64 | 2025 | Supercross, Manta |
| Biosense Webster, INC. | $34.41 | 2024 | Carto 3 |
| Ipsen Biopharmaceuticals, INC | $32.63 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $30.95 | 2023-2024 | Gimoti |
| Fresenius Kabi USA, LLC | $29.55 | 2024 | Idacio |
| Exact Sciences Corporation | $19.67 | 2023 | Cologuard Collection Kit |
| Capsovision, INC. | $19.52 | 2024 | Capsocam Plus |
| W. L. Gore & Associates, INC. | $18.25 | 2020 | |
| Echosens North America, INC. | $13.17 | 2023 | Fibroscan |
| Concordia Pharmaceuticals INC. | $11.46 | 2019 | |
| Organon LLC | $7.49 | 2023 | Renflexis |
| Ambu INC. | $6.18 | 2022 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,028.53 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$43,485.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.